Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDXCNASDAQ:CRONNASDAQ:MNMDNASDAQ:TLRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDXCChromaDex$6.16$2.31▼$9.18$611.50M2.21768,762 shs554,788 shsCRONCronos Group$2.09+1.0%$1.84$1.60▼$2.84$805.50M1.061.29 million shs3.00 million shsMNMDMind Medicine (MindMed)$7.60+8.4%$6.16$4.70▼$10.44$572.80M2.521.38 million shs4.06 million shsTLRYTilray$0.450.0%$0.53$0.41▼$2.15$455.84M1.9528.03 million shs18.92 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDXCChromaDex0.00%0.00%0.00%+34.67%+148.89%CRONCronos Group+0.97%+2.45%+18.08%+6.63%-24.82%MNMDMind Medicine (MindMed)+8.42%+19.31%+31.72%-8.21%-6.46%TLRYTilray-0.04%+0.56%+0.64%-48.16%-76.65%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDXCChromaDex2.3569 of 5 stars3.50.00.04.00.00.01.9CRONCronos Group0.9859 of 5 stars0.03.00.00.03.30.01.3MNMDMind Medicine (MindMed)2.29 of 5 stars3.71.00.00.03.90.80.6TLRYTilray1.4468 of 5 stars3.11.00.00.02.00.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDXCChromaDex 3.00Buy$9.03∞ UpsideCRONCronos Group 0.00N/AN/AN/AMNMDMind Medicine (MindMed) 3.31Buy$25.11230.41% UpsideTLRYTilray 2.25Hold$1.92323.20% UpsideCurrent Analyst Ratings BreakdownLatest TLRY, CRON, CDXC, and MNMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025MNMDMind Medicine (MindMed)Cantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025MNMDMind Medicine (MindMed)Chardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/14/2025TLRYTilrayRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral4/9/2025TLRYTilrayPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$2.00 ➝ $1.003/17/2025CDXCChromaDexHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.003/10/2025CDXCChromaDexHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$8.00 ➝ $11.003/7/2025MNMDMind Medicine (MindMed)Robert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$27.00 ➝ $16.003/7/2025MNMDMind Medicine (MindMed)HC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$55.00 ➝ $55.003/5/2025CDXCChromaDexLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$6.80 ➝ $8.10(Data available from 5/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDXCChromaDex$99.60M0.00N/AN/A$0.38 per share0.00CRONCronos Group$124.59M6.47N/AN/A$2.87 per share0.73MNMDMind Medicine (MindMed)N/AN/AN/AN/A$1.90 per shareN/ATLRYTilray$210.48M2.17N/AN/A$4.14 per share0.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDXCChromaDex-$4.94M$0.10787.290.00N/A1.62%4.85%2.70%N/ACRONCronos Group-$73.96M$0.13N/A69.671.74-42.65%-2.56%-2.47%N/AMNMDMind Medicine (MindMed)-$95.73M-$1.29N/AN/AN/AN/A-47.56%-35.55%N/ATLRYTilray-$244.98M-$1.05N/AN/AN/A-30.95%-4.40%-3.57%8/4/2025 (Estimated)Latest TLRY, CRON, CDXC, and MNMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CRONCronos Group$0.01$0.02+$0.01$0.02$45.44 million$33.62 million5/8/2025Q1 2025MNMDMind Medicine (MindMed)-$0.36-$0.35+$0.01-$0.35N/AN/A4/8/2025Q3 2025TLRYTilray-$0.04-$0.10-$0.06-$0.87$213.38 million$185.78 million3/6/2025Q4 2024MNMDMind Medicine (MindMed)-$0.33-$0.41-$0.08-$0.41N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDXCChromaDexN/AN/AN/AN/AN/ACRONCronos GroupN/AN/AN/AN/AN/AMNMDMind Medicine (MindMed)N/AN/AN/AN/AN/ATLRYTilrayN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDXCChromaDexN/A2.952.35CRONCronos GroupN/A24.2423.05MNMDMind Medicine (MindMed)0.099.009.00TLRYTilray0.102.541.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDXCChromaDex15.41%CRONCronos Group8.71%MNMDMind Medicine (MindMed)27.91%TLRYTilray9.35%Insider OwnershipCompanyInsider OwnershipCDXCChromaDex9.64%CRONCronos Group7.30%MNMDMind Medicine (MindMed)2.45%TLRYTilray0.87%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDXCChromaDex12077.75 million69.02 millionOptionableCRONCronos Group450385.41 million356.14 millionOptionableMNMDMind Medicine (MindMed)4075.37 million71.68 millionOptionableTLRYTilray2,6501.01 billion929.50 millionOptionableTLRY, CRON, CDXC, and MNMD HeadlinesRecent News About These CompaniesTilray (NASDAQ:TLRY) Shares Down 6.9% - Should You Sell?May 20 at 4:43 PM | marketbeat.comTidal Investments LLC Has $14.09 Million Position in Tilray Inc (NASDAQ:TLRY)May 20 at 6:16 AM | marketbeat.comTilray Brands (NasdaqGS:TLRY) Plans Reverse Stock SplitMay 17, 2025 | finance.yahoo.comTilray (NASDAQ:TLRY) Trading Up 4.5% - Time to Buy?May 17, 2025 | marketbeat.comTilray (NASDAQ:TLRY) Shares Down 4.4% - Time to Sell?May 16, 2025 | marketbeat.comTilray (NASDAQ:TLRY) Stock Price Down 1.4% - Here's What HappenedMay 15, 2025 | marketbeat.comTilray (NASDAQ:TLRY) Stock Price Down 2.1% - Should You Sell?May 14, 2025 | marketbeat.comTilray Brands Announces the Launch of XMG Atomic Sours: New THC Beverages and EdiblesMay 14, 2025 | globenewswire.comTilray Inc (NASDAQ:TLRY) Shares Purchased by Dimensional Fund Advisors LPMay 14, 2025 | marketbeat.comTilray (NASDAQ:TLRY) Stock Price Up 1.2% - Here's WhyMay 13, 2025 | marketbeat.comBest Canadian Marijuana Stocks for U.S. Market ExposureMay 13, 2025 | marijuanastocks.com2 Stocks Near Their 52-Week Lows That Still Aren't Worth BuyingMay 13, 2025 | fool.comTilray (NASDAQ:TLRY) Shares Down 2.1% - Here's WhyMay 10, 2025 | marketbeat.comTilray (NASDAQ:TLRY) Trading Up 1.5% - Time to Buy?May 9, 2025 | marketbeat.comTop 3 Marijuana Stocks For Better Investing 2025May 9, 2025 | marijuanastocks.com1 Beaten-Down Stock-Split Company to Avoid in 2025 and BeyondMay 9, 2025 | fool.comTilray (NASDAQ:TLRY) Trading 2.6% Higher - Should You Buy?May 8, 2025 | marketbeat.comCannabis Stock Tilray Brands Loses 19% in a Month: Time to Sell or Hold?May 8, 2025 | zacks.comShock Top: A Bold Rebrand for a Craft Beer IconMay 8, 2025 | globenewswire.comTilray (NASDAQ:TLRY) Trading Down 1% - What's Next?May 7, 2025 | marketbeat.comWhat's Going On With Tilray Brands Stock On Tuesday?May 6, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTLRY, CRON, CDXC, and MNMD Company DescriptionsChromaDex NASDAQ:CDXCChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.Cronos Group NASDAQ:CRON$2.09 +0.02 (+0.97%) As of 05/20/2025 04:00 PM EasternCronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.Mind Medicine (MindMed) NASDAQ:MNMD$7.60 +0.59 (+8.42%) As of 05/20/2025 04:00 PM EasternMind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.Tilray NASDAQ:TLRY$0.45 0.00 (-0.04%) As of 05/20/2025 04:00 PM EasternTilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Viking Holdings Posts Strong Q1, Eyes Growth Ahead 2 Reasons Netflix’s 40% Rally Is Far From Over Hims & Hers Stock Chart Points to Strong Bullish Continuation Boeing Landed New Deals With China and the Saudis for More Upside CrowdStrike’s Rally Faces a Test—Here’s Why That’s Good NVIDIA-Backed CoreWeave Jumps 28%: Is It The Next Great AI Buy? UnitedHealth Insiders Double Down: Is UNH Stock a Value Play? Walmart Stock Holds as Tariff Risk Spurs Support Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
